Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BEAM
stocks logo

BEAM

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
13.29M
+12.91%
-1.108
-0.15%
14.58M
+2.16%
-1.110
-5.13%
18.74M
-37.68%
-1.082
-0.74%
Estimates Revision
The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -13.01% over the past three months. During the same period, the stock price has changed by 22.88%.
Revenue Estimates for FY2025
Revise Downward
down Image
-13.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.57%
In Past 3 Month
Stock Price
Go Up
up Image
+22.88%
In Past 3 Month
14 Analyst Rating
up Image0
Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 44.58 USD with a low forecast of 20.00 USD and a high forecast of 80.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 20.890
sliders
Low
20.00
Averages
44.58
High
80.00
up Image0
Current: 20.890
sliders
Low
20.00
Averages
44.58
High
80.00
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$80
2025-04-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$80
2025-04-07
Reiterates
Strong Buy
Reason
B of A Securities
Alec Stranahan
Hold
to
Strong Buy
Upgrades
$42
2025-03-28
Reason
B of A Securities
Alec Stranahan
Price Target
$42
2025-03-28
Upgrades
Hold
to
Strong Buy
Reason
Cantor Fitzgerald
Rick Bienkowski
Buy
Reiterates
n/a
2025-03-12
Reason
Cantor Fitzgerald
Rick Bienkowski
Price Target
n/a
2025-03-12
Reiterates
Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$80
2025-03-10
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$80
2025-03-10
Reiterates
Strong Buy
Reason
Jones Trading
Soumit Roy
Hold
to
Strong Buy
Upgrades
$34
2025-03-10
Reason
Jones Trading
Soumit Roy
Price Target
$34
2025-03-10
Upgrades
Hold
to
Strong Buy
Reason
JonesResearch upgraded Beam Therapeutics to Buy from Hold with a $34 price target.
Scotiabank
Greg Harrison
Hold
to
Buy
Upgrades
$40
2025-03-10
Reason
Scotiabank
Greg Harrison
Price Target
$40
2025-03-10
Upgrades
Hold
to
Buy
Reason
Scotiabank raised the firm's price target on Beam Therapeutics to $25 from $24 and keeps a Sector Perform rating on the shares. The firm likes the company's setup for the rest of the year, but remains cautious until more clinical derisking occurs, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Beam Therapeutics Inc (BEAM.O) is -4.51, compared to its 5-year average forward P/E of -11.28. For a more detailed relative valuation and DCF analysis to assess Beam Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.28
Current PE
-4.51
Overvalued PE
-3.44
Undervalued PE
-19.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.15
Current EV/EBITDA
-2.22
Overvalued EV/EBITDA
0.30
Undervalued EV/EBITDA
-18.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7382.33
Current PS
32.70
Overvalued PS
42036.92
Undervalued PS
-27272.25

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 161.22% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BEAM News & Events

Events Timeline

(ET)
2025-06-13
07:01:45
Beam Therapeutics announces new data from BEACON Phase 1/2 trial
select
2025-06-03 (ET)
2025-06-03
07:04:59
Beam Therapeutics announces U.S. FDA granted ODD to BEAM-101
select
2025-05-30 (ET)
2025-05-30
14:57:01
Beam Therapeutics treatment of sickle cell disease granted orphan designation
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
07-08TipRanks
Cathie Wood Starts This Volatile Week with $13M Buy and a Key Sell-Off

  • ARK Invest's Trading Moves: Cathie Wood's ARK Invest increased its stake in Beam Therapeutics by purchasing over 659,000 shares for more than $13.2 million while reducing its investment in Roblox by selling 31,416 shares worth approximately $3.25 million.

  • Market Sentiment on Stocks: Analysts are optimistic about Beam Therapeutics, giving it a Strong Buy rating with significant upside potential, while Roblox has a Moderate Buy consensus despite recent share sales by ARK.

Preview
4.0
07-06Yahoo Finance
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

  • Beam Therapeutics Overview: Beam Therapeutics Inc. is recognized as one of the top pharmaceutical stocks, with a Buy rating and a price target of $80 set by H.C. Wainwright analyst Patrick Trucchio, driven by its promising gene editing pipeline and ongoing clinical programs for diseases like sickle cell disease and alpha-1 antitrypsin deficiency.

  • Future Prospects: The company is expected to achieve significant milestones, including the initiation of Phase 1 trials and advancements in its manufacturing capabilities, which positions it well for delivering innovative genetic therapies and enhances investor interest.

Preview
5.0
07-04TipRanks
Cathie Wood Marks Independence Day with Strategic Buys and a Major Sell-Off

  • Cathie Wood's Recent Trades: On July 3, hedge fund manager Cathie Wood sold 20,506 shares of Japan’s Komatsu Ltd. and purchased 28,743 shares of Beam Therapeutics, indicating a strong belief in the company's future potential.

  • Increased Holdings in Pharmaceuticals: Wood also expanded her investment in Compass Pathways Plc by acquiring 125,491 shares, reflecting a growing interest in psychedelic pharmaceuticals alongside positive analyst ratings for Beam Therapeutics.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Beam Therapeutics Inc (BEAM) stock price today?

The current price of BEAM is 20.89 USD — it has increased 4.09 % in the last trading day.

arrow icon

What is Beam Therapeutics Inc (BEAM)'s business?

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

arrow icon

What is the price predicton of BEAM Stock?

Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 44.58 USD with a low forecast of 20.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Beam Therapeutics Inc (BEAM)'s revenue for the last quarter?

Beam Therapeutics Inc revenue for the last quarter amounts to 7.47M USD, increased 0.81 % YoY.

arrow icon

What is Beam Therapeutics Inc (BEAM)'s earnings per share (EPS) for the last quarter?

Beam Therapeutics Inc. EPS for the last quarter amounts to -1.24 USD, increased 2.48 % YoY.

arrow icon

What changes have occurred in the market's expectations for Beam Therapeutics Inc (BEAM)'s fundamentals?

The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -13.01% over the past three months. During the same period, the stock price has changed by 22.88%.
arrow icon

How many employees does Beam Therapeutics Inc (BEAM). have?

Beam Therapeutics Inc (BEAM) has 483 emplpoyees as of July 18 2025.

arrow icon

What is Beam Therapeutics Inc (BEAM) market cap?

Today BEAM has the market capitalization of 2.02B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free